Time to change

Nostrapharmus predicts that a more strategic and proactive approach to safety will win back consumer confidence.

Drug safety in pharma is under extreme pressure right now.  Trusted blue chip organisations have been publicly accused of putting profits ahead of patient safety, and negative stories in the media are fueling public and stakeholder anxiety.    Legislators and regulators are feeling twitchy, and are demanding proof from all pharma companies that their teams are building safety risk management into everything they do.  The overall result is severe demand on the industry to prove that patient safety forms the nucleus of all work done whilst developing a drug from conception to clinical and through to manufacturing and marketing.  This means that pharma's drug safety units are being asked to take a much wider, more strategic look at a drug's safety profile, starting as early as possible in the product's life cycle.

If you would like to view the article in full please click on the pdf link below:

Time to Change

or to view the magazine follow the link below, the article can be found on pages 57 and 58:

http://viewer.zmags.com/showmag.php?mid=pfrpd#/page56/

About Pharma magazine
Aimed at the international pharmaceutical and bio-pharmaceutical community, Pharma magazine covers every aspect of manufacturing from R&D to finished product. With a worldwide circulation of more than 40,000 individuals it is the first truly global magazine for the pharma industry, bringing together the disciplines of discovery and development, the drug manufacturing process and the resultant business and management issues.

For further information visit the Pharma magazine website www.pharma-mag.com